OPHELIA

EFFECTIVENESS OF OLAPARIB PLUS TRASTUZUMAB IN HER2-POSITIVE BRCA-MUTATED ADVANCED BREAST CANCER PATIENTS (THE OPHELIA STUDY)

CLINICAL TRIAL DETAILS

THE OPHELIA STUDY IS A MULTICENTER, OPEN-LABEL, SINGLE-ARM, TWO COHORTS, SIMON’S TWO-STAGE MINIMAX DESIGN, PHASE II CLINICAL TRIAL. THE PRIMARY OBJECTIVE OF THIS TRIAL IS TO ASSESS THE EFFICACY – AS DETERMINED BY THE OVERALL RESPONSE RATE (ORR) AND PROGRESSION-FREE SURVIVAL (PFS) BASED ON RECIST V.1.1 – OF OLAPARIB IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE, GERMINAL BRCA1/2 MUTATED ABC.

OPHELIA AT CLINICALTRIALS.GOV

COUNTRY

STATUS

TUMOR TYPE

PHASE

SITES

BREAST

Spain

Closed

TRIAL OVERVIEW

PRESS RELEASE

----

SCIENTIFIC IMPACT

ESMO 2019 poster

SABCS 2022 poster

BLOG ARTICLES RELATED

First Patient in OPHELIA Study

TRIAL SITES

Hospital Arnau de Vilanova de Valencia (Spain) Complejo Hospitalario de Jaén (Spain) Hospital Universitario Virgen del Rocío (Spain) Onkologikoa (Spain) Hospital Clínico San Carlos (Spain) Hospital Son Llatzer (Spain) Hospital Universitario Virgen de la Victoria (Spain) Hospital Universitari Son Espases (Spain) Hospital Universitari Vall D'Hebron (Spain) Hospital Universitario Arnau de Vilanova de Lleida (Spain) Complejo Hospitalario Universitario de Santiago (CHUS) (Spain) Hospital San Pedro de Alcántara (Spain) Complejo Asistencial de Ávila (Spain) Hospital Clínico Universitario de Valencia (Spain) Hospital Universitario Reina Sofía (Spain) Hospital Universitario Ramón y Cajal (Spain) Hospital Universitario La Paz (Spain)

Dr. Cortes and Dr. Llombart PHERain interview

Beyond Chemotherapy

Dr. Vanes Quiroga

Dr. Sofia Braga

Dr. Silvi Antolín

Dr. Escrivá de Romaní

Dr. Philipp Aftimos

Dr. Manuel Ruiz

Prof. Daniele Generali PHEGain interview

Dr. Jacques Medioni

Dr. Dunca Wheatley